{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T23:54:42Z","timestamp":1793836482745,"version":"4.6.1"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1038\/s41375-025-02712-5","type":"journal-article","created":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T07:35:34Z","timestamp":1754033734000},"page":"2504-2515","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["The bone marrow immune ecosystem shapes daratumumab acquired resistance in plasma cell myeloma"],"prefix":"10.1038","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5836-0872","authenticated-orcid":false,"given":"Yun","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuzhao","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-4533-8254","authenticated-orcid":false,"given":"Zhijian","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert Peter","family":"Gale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shutong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoqin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peidong","family":"Chi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiling","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingchun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8272-5421","authenticated-orcid":false,"given":"Weida","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0909-4731","authenticated-orcid":false,"given":"Juan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-8410-2817","authenticated-orcid":false,"given":"Zhongjun","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4226-9580","authenticated-orcid":false,"given":"Yang","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2145-6643","authenticated-orcid":false,"given":"Xiaojun","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,1]]},"reference":[{"key":"2712_CR1","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1634\/theoncologist.2016-0104","volume":"21","author":"S Usmani","year":"2016","unstructured":"Usmani S, Ahmadi T, Ng Y, Lam A, Desai A, Potluri R, et al. Analysis of real-world data on overall survival in multiple myeloma patients with \u22653 prior lines of therapy including a proteasome inhibitor (PI) and an immunomodulatory drug (IMiD), or double refractory to a PI and an IMiD. Oncologist. 2016;21:1355\u201361.","journal-title":"Oncologist"},{"key":"2712_CR2","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1182\/blood-2016-03-705210","volume":"128","author":"SZ Usmani","year":"2016","unstructured":"Usmani SZ, Weiss BM, Plesner T, Bahlis NJ, Belch A, Lonial S, et al. Clinical efficacy of daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma. Blood. 2016;128:37\u201344.","journal-title":"Blood"},{"key":"2712_CR3","doi-asserted-by":"publisher","first-page":"1501","DOI":"10.1007\/s00277-023-05188-4","volume":"102","author":"M Stork","year":"2023","unstructured":"Stork M, Spicka I, Radocha J, Minarik J, Jelinek T, Jungova A, et al. Daratumumab with lenalidomide and dexamethasone in relapsed or refractory multiple myeloma patients - real-world evidence analysis. Ann Hematol. 2023;102:1501\u201311.","journal-title":"Ann Hematol"},{"key":"2712_CR4","doi-asserted-by":"publisher","first-page":"7498","DOI":"10.1158\/1078-0432.CCR-17-2027","volume":"23","author":"J Krejcik","year":"2017","unstructured":"Krejcik J, Frerichs KA, Nijhof IS, van Kessel B, van Velzen JF, Bloem AC, et al. Monocytes and granulocytes reduce CD38 expression levels on myeloma cells in patients treated with daratumumab. Clin Cancer Res. 2017;23:7498\u2013511.","journal-title":"Clin Cancer Res"},{"key":"2712_CR5","doi-asserted-by":"publisher","first-page":"99","DOI":"10.2119\/molmed.2013.00009","volume":"19","author":"A Chillemi","year":"2013","unstructured":"Chillemi A, Zaccarello G, Quarona V, Ferracin M, Ghimenti C, Massaia M, et al. Anti-CD38 antibody therapy: windows of opportunity yielded by the functional characteristics of the target molecule. Mol Med. 2013;19:99\u2013108.","journal-title":"Mol Med"},{"key":"2712_CR6","doi-asserted-by":"publisher","first-page":"2134","DOI":"10.3389\/fimmu.2018.02134","volume":"9","author":"N van de Donk","year":"2018","unstructured":"van de Donk N, Usmani SZ. CD38 antibodies in multiple myeloma: mechanisms of action and modes of resistance. Front Immunol. 2018;9:2134.","journal-title":"Front Immunol"},{"key":"2712_CR7","doi-asserted-by":"crossref","unstructured":"Saltarella I, Desantis V, Melaccio A, Solimando AG, Lamanuzzi A, Ria R, et al. Mechanisms of resistance to anti-CD38 daratumumab in multiple myeloma. Cells. 2020;9:167.","DOI":"10.3390\/cells9010167"},{"key":"2712_CR8","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1182\/blood.V130.Suppl_1.63.63","volume":"130","author":"P Neri","year":"2017","unstructured":"Neri P, Maity R, Tagoug I, Duggan P, McCulloch S, Jimenez-Zepeda V, et al. Single cell resolution profiling defines the innate and adaptive immune repertoires modulated by daratumumab and imids treatment in multiple myeloma (MM). Blood. 2017;130:123.","journal-title":"Blood"},{"key":"2712_CR9","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2017.1386361","volume":"7","author":"PE van Bommel","year":"2018","unstructured":"van Bommel PE, He Y, Schepel I, Hendriks M, Wiersma VR, van Ginkel RJ, et al. CD20-selective inhibition of CD47-SIRP\u03b1 \u201cdon\u2019t eat me\u201d signaling with a bispecific antibody-derivative enhances the anticancer activity of daratumumab, alemtuzumab and obinutuzumab. Oncoimmunology. 2018;7:e1386361.","journal-title":"Oncoimmunology"},{"key":"2712_CR10","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1182\/blood-2016-03-703439","volume":"128","author":"IS Nijhof","year":"2016","unstructured":"Nijhof IS, Casneuf T, van Velzen J, van Kessel B, Axel AE, Syed K, et al. CD38 expression and complement inhibitors affect response and resistance to daratumumab therapy in myeloma. Blood. 2016;128:959\u201370.","journal-title":"Blood"},{"key":"2712_CR11","doi-asserted-by":"publisher","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","volume":"17","author":"S Kumar","year":"2016","unstructured":"Kumar S, Paiva B, Anderson KC, Durie B, Landgren O, Moreau P, et al. International myeloma working group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 2016;17:e328\u2013e46.","journal-title":"Lancet Oncol"},{"key":"2712_CR12","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms6641","volume":"5","author":"F Porichis","year":"2014","unstructured":"Porichis F, Hart MG, Griesbeck M, Everett HL, Hassan M, Baxter AE, et al. High-throughput detection of miRNAs and gene-specific mRNA at the single-cell level by flow cytometry. Nat Commun. 2014;5:5641.","journal-title":"Nat Commun"},{"key":"2712_CR13","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1038\/s41587-020-0472-9","volume":"38","author":"CR Merritt","year":"2020","unstructured":"Merritt CR, Ong GT, Church SE, Barker K, Danaher P, Geiss G, et al. Multiplex digital spatial profiling of proteins and RNA in fixed tissue. Nat Biotechnol. 2020;38:586\u201399.","journal-title":"Nat Biotechnol"},{"key":"2712_CR14","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2105-14-7","volume":"14","author":"S Hanzelmann","year":"2013","unstructured":"Hanzelmann S, Castelo R, Guinney J. GSVA: gene set variation analysis for microarray and RNA-seq data. BMC Bioinforma. 2013;14:7.","journal-title":"BMC Bioinforma"},{"key":"2712_CR15","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1007\/s11626-010-9333-z","volume":"46","author":"R Barallon","year":"2010","unstructured":"Barallon R, Bauer SR, Butler J, Capes-Davis A, Dirks WG, Elmore E, et al. Recommendation of short tandem repeat profiling for authenticating human cell lines, stem cells, and tissues. Vitro Cell Dev Biol Anim. 2010;46:727\u201332.","journal-title":"Vitro Cell Dev Biol Anim"},{"key":"2712_CR16","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1038\/nbt.1665","volume":"28","author":"L Shi","year":"2010","unstructured":"Shi L, Campbell G, Jones WD, Campagne F, Wen Z, Walker SJ, et al. The MicroArray Quality Control (MAQC)-II study of common practices for the development and validation of microarray-based predictive models. Nat Biotechnol. 2010;28:827\u201338.","journal-title":"Nat Biotechnol"},{"key":"2712_CR17","doi-asserted-by":"publisher","first-page":"2410","DOI":"10.1038\/leu.2014.232","volume":"28","author":"CJ Heuck","year":"2014","unstructured":"Heuck CJ, Qu P, van Rhee F, Waheed S, Usmani SZ, Epstein J, et al. Five gene probes carry most of the discriminatory power of the 70-gene risk model in multiple myeloma. Leukemia. 2014;28:2410\u201313.","journal-title":"Leukemia"},{"key":"2712_CR18","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1003323","volume":"17","author":"SA Danziger","year":"2020","unstructured":"Danziger SA, McConnell M, Gockley J, Young MH, Rosenthal A, Schmitz F, et al. Bone marrow microenvironments that contribute to patient outcomes in newly diagnosed multiple myeloma: a cohort study of patients in the Total Therapy clinical trials. PLoS Med. 2020;17:e1003323.","journal-title":"PLoS Med"},{"key":"2712_CR19","doi-asserted-by":"publisher","first-page":"1878","DOI":"10.1038\/s41588-024-01853-0","volume":"56","author":"S Skerget","year":"2024","unstructured":"Skerget S, Penaherrera D, Chari A, Jagannath S, Siegel DS, Vij R, et al. Comprehensive molecular profiling of multiple myeloma identifies refined copy number and expression subtypes. Nat Genet. 2024;56:1878\u201389.","journal-title":"Nat Genet"},{"key":"2712_CR20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41577-020-00486-8","volume":"21","author":"A Flemming","year":"2021","unstructured":"Flemming A. GZMK+ T cells a hallmark of immune ageing. Nat Rev Immunol. 2021;21:1\u20131.","journal-title":"Nat Rev Immunol"},{"key":"2712_CR21","doi-asserted-by":"publisher","first-page":"2546","DOI":"10.1182\/blood.2023020050","volume":"141","author":"MY Kim","year":"2023","unstructured":"Kim MY. CXCR4 to improve both T cell homing and function. Blood. 2023;141:2546\u201347.","journal-title":"Blood"},{"key":"2712_CR22","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1038\/s41586-022-04632-1","volume":"605","author":"C Chou","year":"2022","unstructured":"Chou C, Zhang X, Krishna C, Nixon BG, Dadi S, Capistrano KJ, et al. Programme of self-reactive innate-like T cell-mediated cancer immunity. Nature. 2022;605:139\u201345.","journal-title":"Nature"},{"key":"2712_CR23","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.bioactmat.2023.08.001","volume":"31","author":"H Zhang","year":"2024","unstructured":"Zhang H, Yang L, Wang T, Li Z. NK cell-based tumor immunotherapy. Bioactive Mater. 2024;31:63\u201386.","journal-title":"Bioactive Mater"},{"key":"2712_CR24","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1038\/35869","volume":"391","author":"VM Braud","year":"1998","unstructured":"Braud VM, Allan DSJ, O\u2019Callaghan CA, S\u00f6derstr\u00f6m K, D\u2019Andrea A, Ogg GS, et al. HLA-E binds to natural killer cell receptors CD94\/NKG2A, B and C. Nature. 1998;391:795\u201399.","journal-title":"Nature"},{"key":"2712_CR25","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1038\/s41591-021-01232-w","volume":"27","author":"YC Cohen","year":"2021","unstructured":"Cohen YC, Zada M, Wang SY, Bornstein C, David E, Moshe A, et al. Identification of resistance pathways and therapeutic targets in relapsed multiple myeloma patients through single-cell sequencing. Nat Med. 2021;27:491\u2013503.","journal-title":"Nat Med"},{"key":"2712_CR26","doi-asserted-by":"crossref","unstructured":"\u00c1lvarez E, Falqui M, Sin L, McGrail JP, Perdiguero B, Coloma R, et al. Unveiling the multifaceted roles of ISG15: from immunomodulation to therapeutic frontiers. Vaccines. 2024;12:153.","DOI":"10.3390\/vaccines12020153"},{"key":"2712_CR27","doi-asserted-by":"crossref","unstructured":"Brown IN, Lafita-Navarro MC, Conacci-Sorrell M. Regulation of nucleolar activity by MYC. Cells. 2022;11:574.","DOI":"10.3390\/cells11030574"},{"key":"2712_CR28","doi-asserted-by":"publisher","first-page":"129","DOI":"10.3389\/fendo.2018.00129","volume":"9","author":"ES Goetzman","year":"2018","unstructured":"Goetzman ES, Prochownik EV. The role for Myc in coordinating glycolysis, oxidative phosphorylation, glutaminolysis, and fatty acid metabolism in normal and neoplastic tissues. Front Endocrinol. 2018;9:129.","journal-title":"Front Endocrinol"},{"key":"2712_CR29","doi-asserted-by":"publisher","first-page":"263","DOI":"10.3324\/haematol.2014.117531","volume":"100","author":"IS Nijhof","year":"2015","unstructured":"Nijhof IS, Lammerts van Bueren JJ, van Kessel B, Andre P, Morel Y, Lokhorst HM, et al. Daratumumab-mediated lysis of primary multiple myeloma cells is enhanced in combination with the human anti-KIR antibody IPH2102 and lenalidomide. Haematologica. 2015;100:263\u20138.","journal-title":"Haematologica"},{"key":"2712_CR30","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1182\/blood-2018-99-117531","volume":"132","author":"P Neri","year":"2018","unstructured":"Neri P, Maity R, Tagoug I, McCulloch S, Duggan P, Jimenez-Zepeda V, et al. Immunome single cell profiling reveals T cell exhaustion with upregulation of checkpoint inhibitors LAG3 and tigit on marrow infiltrating T lymphocytes in daratumumab and IMiDs resistant patients. Blood. 2018;132:242\u201342.","journal-title":"Blood"},{"key":"2712_CR31","doi-asserted-by":"crossref","unstructured":"Verkleij CPM, Jhatakia A, Broekmans MEC, Frerichs KA, Zweegman S, Mutis T, et al. Preclinical rationale for targeting the PD-1\/PD-L1 axis in combination with a CD38 antibody in multiple myeloma and other CD38-positive malignancies. Cancers. 2020;12:3713.","DOI":"10.3390\/cancers12123713"},{"key":"2712_CR32","doi-asserted-by":"publisher","first-page":"1727","DOI":"10.1158\/1538-7445.AM2018-1727","volume":"78","author":"NA Bezman","year":"2018","unstructured":"Bezman NA, Kinder M, Jhatakia AD, Mattson BK, Pizutti D, Thompson EW, et al. Abstract 1727: antitumor activity associated with dual targeting of CD38 and programmed death-1 (PD-1) pathways in preclinical models. Cancer Res. 2018;78:1727\u201327.","journal-title":"Cancer Res"},{"key":"2712_CR33","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1038\/s41577-021-00566-3","volume":"22","author":"AM Gocher","year":"2022","unstructured":"Gocher AM, Workman CJ, Vignali DAA. Interferon-\u03b3: teammate or opponent in the tumour microenvironment?. Nat Rev Immunol. 2022;22:158\u201372.","journal-title":"Nat Rev Immunol"},{"key":"2712_CR34","doi-asserted-by":"publisher","first-page":"1501","DOI":"10.1038\/bjc.2015.101","volume":"112","author":"K Abiko","year":"2015","unstructured":"Abiko K, Matsumura N, Hamanishi J, Horikawa N, Murakami R, Yamaguchi K, et al. IFN-\u03b3 from lymphocytes induces PD-L1 expression and promotes progression of ovarian cancer. Br J Cancer. 2015;112:1501\u201309.","journal-title":"Br J Cancer"},{"key":"2712_CR35","doi-asserted-by":"crossref","unstructured":"Tsai C-H, Chuang Y-M, Li X, Yu Y-R, Tzeng S-F, Teoh ST, et al. Immunoediting instructs tumor metabolic reprogramming to support immune evasion. Cell Metab. 2023;35:118-133.e7","DOI":"10.1016\/j.cmet.2022.12.003"},{"key":"2712_CR36","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-024-01096-6","volume":"14","author":"B Ziccheddu","year":"2024","unstructured":"Ziccheddu B, Giannotta C, D\u2019Agostino M, Bertuglia G, Saraci E, Oliva S, et al. Genomic and immune determinants of resistance to daratumumab-based therapy in relapsed refractory multiple myeloma. Blood Cancer J. 2024;14:117.","journal-title":"Blood Cancer J"},{"key":"2712_CR37","doi-asserted-by":"publisher","first-page":"1660","DOI":"10.1038\/s43018-023-00657-1","volume":"4","author":"F Maura","year":"2023","unstructured":"Maura F, Boyle EM, Coffey D, Maclachlan K, Gagler D, Diamond B, et al. Genomic and immune signatures predict clinical outcome in newly diagnosed multiple myeloma treated with immunotherapy regimens. Nature Cancer. 2023;4:1660\u201374.","journal-title":"Nature Cancer"},{"key":"2712_CR38","doi-asserted-by":"crossref","unstructured":"Starska-Kowarska K. The role of different immunocompetent cell populations in the pathogenesis of head and neck cancer-regulatory mechanisms of pro- and anti-cancer activity and their impact on immunotherapy. Cancers. 2023;15:1642.","DOI":"10.3390\/cancers15061642"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41375-025-02712-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-025-02712-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-025-02712-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T08:12:23Z","timestamp":1758787943000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41375-025-02712-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,1]]},"references-count":38,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["2712"],"URL":"https:\/\/doi.org\/10.1038\/s41375-025-02712-5","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,1]]},"assertion":[{"value":"5 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 June 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 July 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 August 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"RPG is a consultant to Antengene Biotech LLC, Ascentage Pharma Group and NexImmune Inc.; Medical Director, FFF Enterprises Inc.; Board of Directors: Russian Foundation for Cancer Research Support; and Scientific Advisory Boards, Nanexa AB and StemRad Ltd.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The study was approved by the Ethics Committee of Sun Yat-sen University. Subjects gave written informed consent consistent with the precepts of the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}}]}}